Tradestie Institutional Equity Comparison Engine

SRZN vs BOLD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (3โ€“0 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus BOLD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against BOLD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SRZN N/M vs BOLD N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin -485.4% vs 0.0% ยท YoY +408.6% vs +0.0%
Momentum & Technical Winner SRZN
1Y +110.8% vs +101.7% ยท 52W Pos 63% vs 62%
Options & Structure Winner SRZN
CONSOLIDATION (13th %ile IV) vs UNCLASSIFIED (N/A IV)
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
1M Return +10.52%
1Y Return +110.81%
Forward P/E N/M
Unified AI Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0
BOLD NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
1M Return -4.92%
1Y Return +101.74%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRZN +110.81% BOLD +101.74% Spread: +9.07 pp (SRZN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SRZN TTM Op. Margin: -485.4% BOLD TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRZN vs BOLD. Trailing 12-month operating profitability (SRZN -485.4% vs BOLD 0.0%) and valuation multiples (SRZN N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRZN (4) vs BOLD (3)
Institutional Metric SRZN BOLD Criterion Row Winner
Market Capitalization Scale $642.7M $56.2M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +408.6% +0.0% Higher Growth SRZN
Operating Margin (TTM) Profitability -485.4% 0.0% Higher Margin BOLD
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.8% -64.6% Higher ROE SRZN
52-Week Range Position Momentum 63% ($13โ€“$38) 62% ($1โ€“$3) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.29ฮฒ ยท 73% Vol -0.08ฮฒ ยท 28% Vol Lower Realized Risk BOLD
Unified Institutional Score Composite Signal 36.0 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite BOLD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRZN vs BOLD Buy Guide
SRZN CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BOLD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BOLD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRZN nor BOLD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.